Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1406&sort=title
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=title", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=title", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1407&sort=title", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=title" }, "data": [ { "type": "Grant", "id": "9734", "attributes": { "award_id": "1R01AG074307-01A1", "title": "Viral IncRNAs Regulate Host Genomic Transcriptional Programs Associated with Sporadic Alzheimer's Disease", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 21712, "first_name": "Miroslaw", "last_name": "Mackiewicz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-07-01", "end_date": "2027-06-30", "award_amount": 416540, "principal_investigator": { "id": 25575, "first_name": "MICHAEL G", "last_name": "ROSENFELD", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 760, "ror": "https://ror.org/0168r3w48", "name": "University of California, San Diego", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Alzheimer’s disease (AD) presents a formidable therapeutic challenge, as current interventions have failed to slow disease progression. The majority of AD genetic risk variants identified by GWAS reside in non- coding regions of the genome, suggesting that alterations in gene expression contribute to susceptibility for sporadic AD. Multiple reports now suggest that Herpes Simplex Virus 1 (HSV1) and other microbes can accumulate in the brain to increase the incidence of AD/dementia. While there is evidence linking reactivation of latent HSV1 infection to AD, the pathological potential of the latent state per se has not been addressed. Furthermore, there is now concern that COVID-19, which is caused by the pandemic SARS-CoV-2 and can include neurological and neurocognitive sequelae, might impact the onset or course of AD. Here we propose to advance recent findings by employing powerful new genomic technologies to characterize the cell type-specific transcriptional impact and cell autonomous vs non-cell autonomous effects of specific viral gene products, including HSV1 latency lncRNA transcripts and the SARS-CoV-2 Spike protein, that contribute to neurotoxic programs characteristic of sporadic AD. Using a modified single-nucleus sequencing approach, which allows for DNA accessibility and global transcription to be assessed simultaneously in the same nucleus, we will continue our interrogation of human control and AD brain samples to reveal cell type-specific aging vs pathological trajectory trees for each CNS cell type in sporadic AD, ultimately allowing for the identification of the key transcription factors acting at implicated regulatory enhancers. This will enable us to elucidate how viral gene products alter enhancer landscapes and transcriptional networks related to sporadic AD in various neuronal and non-neuronal cell types and subtypes. In addition, we will investigate the hypothesis that the sense (S) and antisense (AS) LATs impact transcription by associating with specific regulatory elements in the host genome in collaboration with the co-regulator KAP1 to impact expression of multiple AD susceptibility loci. We further hypothesize that the S-LAT influences the AD process by causing neuronal dysfunction and inflammatory glial activation, at least in part, through down-regulation of gene clusters encoding KRAB zinc-finger proteins (KZFPs) that normally repress human endogenous retrovirus (HERV) repeats, whereas the AS-LAT tempers these deleterious effects by promoting an anti-inflammatory gene expression profile and can further mitigate the innate immune response as well as cell death programs through direct inhibition of the AD-associated, sentinel kinase PKR in a non-genomic fashion. Collectively, the proposed studies will yield crucial cell type-specific insights into pathological trajectories in sporadic AD that may be subject to modulation by diverse infectious as well as non- microbial insults to the brain.", "keywords": [ "2019-nCoV", "Address", "Affect", "Aging", "Alzheimer&apos", "s Disease", "Alzheimer&apos", "s disease brain", "Alzheimer&apos", "s disease model", "Alzheimer&apos", "s disease pathology", "Alzheimer&apos", "s disease patient", "Alzheimer&apos", "s disease risk", "Amyloid", "Anti-Inflammatory Agents", "Appearance", "Astrocytes", "Attention", "Binding", "Biological Models", "Brain", "COVID-19", "COVID-19 pandemic", "Cell Death", "Cell Nucleus", "Cells", "Characteristics", "Collaborations", "DNA", "Data", "Dementia", "Deposition", "Disease", "Disease Progression", "Disease susceptibility", "Double-Stranded RNA", "Down-Regulation", "Ectopic Expression", "Endogenous Retroviruses", "Enhancers", "Etiology", "Event", "Female", "Future", "Gene Cluster", "Gene Expression", "Gene Expression Profile", "Gene Proteins", "Genes", "Genetic", "Genetic Risk", "Genetic Transcription", "Genetic Variation", "Genome", "Genomics", "Glean", "Herpesviridae", "Herpesvirus 1", "Human", "Immune", "Impaired cognition", "Incidence", "Individual", "Infection", "Inflammatory", "Innate Immune Response", "Intervention", "Investigation", "Link", "Microbe", "Microglia", "Molecular", "Mus", "Neurocognitive", "Neurofibrillary Tangles", "Neuroglia", "Neurologic", "Neuronal Dysfunction", "Neurons", "Nucleic Acid Regulatory Sequences", "Pathologic", "Pathway interactions", "Phosphotransferases", "Predisposition", "Process", "Proteins", "Public Health", "Regulation", "Regulatory Element", "Reporting", "Research", "Retrotransposon", "Role", "SARS-CoV-2 spike protein", "Sampling", "Sentinel", "Small Nuclear RNA", "Susceptibility Gene", "Technology", "Testing", "Therapeutic", "Therapeutic Intervention", "Transcript", "Transcription Alteration", "Trees", "United States", "Untranslated RNA", "Up-Regulation", "Viral", "Viral Genome", "Viral Proteins", "Virus", "Virus Diseases", "Zinc Fingers", "aged", "biological specimen archives", "cell type", "extracellular", "gene repression", "genome wide association study", "glial activation", "insight", "latency associated transcript", "latent infection", "male", "neuroinflammation", "neuron loss", "neuropathology", "neurotoxic", "non-genomic", "novel", "novel strategies", "outcome prediction", "programs", "promoter", "reactivation from latency", "recruit", "risk variant", "transcription factor" ], "approved": true } }, { "type": "Grant", "id": "15397", "attributes": { "award_id": "1R13AI186262-01", "title": "Viral Infection and Inflammation Workshop 2024", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 22573, "first_name": "Barbara L.", "last_name": "Mulach", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-17", "end_date": "2025-06-30", "award_amount": 7000, "principal_investigator": { "id": 24861, "first_name": "Daniel R.", "last_name": "Kuritzkes", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 7486, "first_name": "SERENA S", "last_name": "SPUDICH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 891, "ror": "https://ror.org/04b6nzv94", "name": "Brigham and Women's Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Acute and chronic effects of viral diseases often involve immune-mediated responses, including inflammation, immune activation, and autoimmunity. Long-COVID immunopathogenesis is complex but its understanding is advancing rapidly. The consequences of immune-mediated damage in long COVID share similarities (and differences) with other post-viral diseases like Ebola and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). In the case of HIV, ongoing activation of the inflammatory response is a major concern, and immune reconstitution remains limited in some patients even long after treatment initiation. In addition to SARS-CoV-2 and HIV, other viral infections such as CMV are known to result in inflammation- related pathology. Viruses can also trigger autoimmunity. Epstein-Barr Virus is tightly linked with the onset of Multiple Sclerosis through several autoimmune mechanisms. Viral encephalitis also often has an autoimmune background. Common underlying mechanisms imply the possibility of employing similar therapeutic interventions, such as neutralizing antibodies, antiviral drugs, and therapeutic vaccines to eliminate the persistent virus or anti-inflammatory drugs to ameliorate chronic inflammation. Therapeutic interventions must often target both ends of the virus-immune system spectrum. The prevalence of post-acute infectious syndromes is concerning. The severity of the syndrome disables daily activities, posing a significant burden on health, economy, and society. Despite intensive research on cellular and molecular mechanisms, scientific platforms to share data and discuss new concepts are limited to sessions at major international conferences or scientific meetings focusing on a specific condition. This annual workshop links leading international scientific investigators in a discussion of cutting-edge research developments on underlying inflammatory mechanisms related to viral infection, and its clinical implications. Specific aims of the meeting include: 1) providing a global cross-disciplinary platform to exchange knowledge on underlying mechanisms of virus-mediated inflammation; 2) gathering basic, translational, and clinical researchers, and clinicians to stimulate discussion on remaining unknowns; 3) fostering future collaborations among participants; 4) translating the data into clinical guidance; and 5) increasing the visibility of early career investigators and investigators from underrepresented minority (URM) groups and their research, thereby facilitating a generation of future leaders in the field.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10955", "attributes": { "award_id": "5R01CA259386-02", "title": "Viral Noncoding RNAs and Cell Transformation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 21648, "first_name": "Elizabeth Lee", "last_name": "Read-Connole", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-01-20", "end_date": "2026-12-31", "award_amount": 672801, "principal_investigator": { "id": 23667, "first_name": "JOAN A.", "last_name": "STEITZ", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 452, "ror": "https://ror.org/03v76x132", "name": "Yale University", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 452, "ror": "https://ror.org/03v76x132", "name": "Yale University", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "The roles of noncoding (nc)RNAs in lymphoid cells harboring each of three oncogenic herpesviruses are being investigated. Epstein-Barr virus (EBV) infects and transforms human B cells; it is the causative agent of infectious mononucleosis and is associated with several human cancers. Herpesvirus saimiri (HVS) induces fatal lymphomas and leukemias in New World monkeys and transforms human T lymphocytes in culture. Kaposi's sarcoma-associated herpesvirus (KSHV) afflicts immunocompromised individuals and persists in a latent form until lytic activation. In recent years, we have focused our efforts on the structure and functions of the two EBV-encoded EBERs, the seven HVS-encoded HSURs and six HVS microRNAs, as well as the KSHV PAN RNA. These viral ncRNAs are all abundant, conserved between related viruses and bind host proteins to form ncRNPs. Our functional studies have uncovered novel mechanisms of microRNA biogenesis and decay, revealed that viral ncRNPs can be essential for nuclear processes as diverse as viral DNA replication (EBER2) or mRNA export to the cytoplasm (PAN), identified the role of triple helices in RNA stabilization, and contributed important insights into viral evolution. Most compelling is that our studies of viral ncRNAs have uncovered the existence of and begun to elucidate novel cellular mechanisms such as the regulation of cellular microRNA populations and how the polyA tail and 3′UTR may collaborate to stabilize cellular mRNAs. Proposed aims will exploit these advances to further investigate the underlying molecular mechanisms. We shall extend our original discovery of target-directed microRNA decay (TDMD) to identify proteins and additional RNA signals contributing to cellular microRNA degradation, as well as investigate the role of a putative small RNA derived from the SARS-CoV-2 genome in regulating host immune responses, with potential diagnostic/therapeutic implications. We shall establish how its polyA tail as well as internal sequences contribute to PAN RNA's ability to enable the nuclear export of late lytic mRNAs, leading to virion protein production and virion release. We shall search cellular transcriptome databases for the presence of RNA sequence/structure motifs contributing to polyA-3′UTR interactions (and presumably RNA stabilization), as recently revealed by our high-resolution X-ray analyses. Newly discovered triplex-forming elements (ENEs) in coronavirus RNAs will be analyzed for their stabilization activity and possible contributions to viral protein synthesis, with potential therapeutic applications. Extensive interactions between viral transcripts in EBV- infected cells discovered by psoralen crosslinking will be validated and further analyzed.", "keywords": [ "2019-nCoV", "3&apos", "Untranslated Regions", "Adopted", "B-Lymphocytes", "Binding", "Biogenesis", "Biological", "Callithrix", "Cancer Patient", "Cebidae", "Cell Nucleus", "Cell physiology", "Cells", "Collaborations", "Coronavirus", "Cytoplasm", "DNA biosynthesis", "Databases", "Diagnostic", "Elements", "Epstein-Barr virus encoded RNA 2", "Evolution", "Gene Expression", "Genome", "Goals", "Herpesviridae", "Human", "Human Herpesvirus 4", "Human Herpesvirus 8", "Immune response", "Immune signaling", "Immunocompromised Host", "In Vitro", "Individual", "Infection", "Infectious Agent", "Infectious Mononucleosis", "Investigation", "Lymphoid Cell", "Lymphoma", "Lytic", "Lytic Phase", "Malignant Neoplasms", "Mass Spectrum Analysis", "Measurement", "Messenger RNA", "MicroRNAs", "Molecular", "Monkeys", "Mutagenesis", "Nuclear", "Nuclear Export", "Oncogenic", "Poly A", "Polyadenylation", "Population", "Primates", "Process", "Production", "Protein Biosynthesis", "Protein Engineering", "Proteins", "Proteome", "RNA", "RNA Databases", "RNA Sequences", "RNA Stability", "RNA-Binding Proteins", "Resolution", "Ribonucleoproteins", "Roentgen Rays", "Role", "SARS-CoV-2 genome", "SARS-CoV-2 infection", "Saimiriine Herpesvirus 2", "Shapes", "Signal Transduction", "Small RNA", "Structure", "System", "T-Lymphocyte", "Tail", "Testing", "Therapeutic", "Transcript", "Untranslated RNA", "Validation", "Viral", "Viral Proteins", "Virion", "Virus", "cell growth", "cell growth regulation", "cell transformation", "combat", "crosslink", "design", "differential expression", "expectation", "gene function", "insight", "leukemia/lymphoma", "mRNA Export", "messenger ribonucleoprotein", "mutant", "novel", "sarcoma", "transcriptome", "transforming virus", "triple helix", "viral DNA", "viral rescue" ], "approved": true } }, { "type": "Grant", "id": "7841", "attributes": { "award_id": "1R01CA259386-01A1", "title": "Viral Noncoding RNAs and Cell Transformation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 21648, "first_name": "Elizabeth Lee", "last_name": "Read-Connole", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-01-20", "end_date": "2026-12-31", "award_amount": 643517, "principal_investigator": { "id": 23667, "first_name": "JOAN A.", "last_name": "STEITZ", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 452, "ror": "https://ror.org/03v76x132", "name": "Yale University", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 452, "ror": "https://ror.org/03v76x132", "name": "Yale University", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "The roles of noncoding (nc)RNAs in lymphoid cells harboring each of three oncogenic herpesviruses are being investigated. Epstein-Barr virus (EBV) infects and transforms human B cells; it is the causative agent of infectious mononucleosis and is associated with several human cancers. Herpesvirus saimiri (HVS) induces fatal lymphomas and leukemias in New World monkeys and transforms human T lymphocytes in culture. Kaposi's sarcoma-associated herpesvirus (KSHV) afflicts immunocompromised individuals and persists in a latent form until lytic activation. In recent years, we have focused our efforts on the structure and functions of the two EBV-encoded EBERs, the seven HVS-encoded HSURs and six HVS microRNAs, as well as the KSHV PAN RNA. These viral ncRNAs are all abundant, conserved between related viruses and bind host proteins to form ncRNPs. Our functional studies have uncovered novel mechanisms of microRNA biogenesis and decay, revealed that viral ncRNPs can be essential for nuclear processes as diverse as viral DNA replication (EBER2) or mRNA export to the cytoplasm (PAN), identified the role of triple helices in RNA stabilization, and contributed important insights into viral evolution. Most compelling is that our studies of viral ncRNAs have uncovered the existence of and begun to elucidate novel cellular mechanisms such as the regulation of cellular microRNA populations and how the polyA tail and 3′UTR may collaborate to stabilize cellular mRNAs. Proposed aims will exploit these advances to further investigate the underlying molecular mechanisms. We shall extend our original discovery of target-directed microRNA decay (TDMD) to identify proteins and additional RNA signals contributing to cellular microRNA degradation, as well as investigate the role of a putative small RNA derived from the SARS-CoV-2 genome in regulating host immune responses, with potential diagnostic/therapeutic implications. We shall establish how its polyA tail as well as internal sequences contribute to PAN RNA's ability to enable the nuclear export of late lytic mRNAs, leading to virion protein production and virion release. We shall search cellular transcriptome databases for the presence of RNA sequence/structure motifs contributing to polyA-3′UTR interactions (and presumably RNA stabilization), as recently revealed by our high-resolution X-ray analyses. Newly discovered triplex-forming elements (ENEs) in coronavirus RNAs will be analyzed for their stabilization activity and possible contributions to viral protein synthesis, with potential therapeutic applications. Extensive interactions between viral transcripts in EBV- infected cells discovered by psoralen crosslinking will be validated and further analyzed.", "keywords": [ "2019-nCoV", "3&apos", "Untranslated Regions", "Adopted", "B-Lymphocytes", "Binding", "Biogenesis", "Biological", "Callithrix", "Cancer Patient", "Cebidae", "Cell Nucleus", "Cell physiology", "Cells", "Coronavirus", "Cytoplasm", "DNA biosynthesis", "Databases", "Diagnostic", "Elements", "Epstein-Barr virus encoded RNA 2", "Evolution", "Gene Expression", "Genome", "Goals", "Herpesviridae", "Human", "Human Herpesvirus 4", "Human Herpesvirus 8", "Immune response", "Immune signaling", "Immunocompromised Host", "In Vitro", "Individual", "Infection", "Infectious Agent", "Infectious Mononucleosis", "Investigation", "Lymphoid Cell", "Lymphoma", "Lytic", "Lytic Phase", "Malignant Neoplasms", "Mass Spectrum Analysis", "Measurement", "Messenger RNA", "MicroRNAs", "Molecular", "Monkeys", "Mutagenesis", "Nuclear", "Nuclear Export", "Oncogenic", "Poly A", "Population", "Primates", "Process", "Production", "Protein Biosynthesis", "Protein Engineering", "Proteins", "Proteome", "Psoralens", "RNA", "RNA Databases", "RNA Sequences", "RNA Stability", "RNA-Binding Proteins", "Resolution", "Ribonucleoproteins", "Roentgen Rays", "Role", "SARS-CoV-2 genome", "SARS-CoV-2 infection", "Saimiriine Herpesvirus 2", "Shapes", "Signal Transduction", "Small RNA", "Structure", "System", "T-Lymphocyte", "Tail", "Testing", "Therapeutic", "Transcript", "Untranslated RNA", "Viral", "Viral Proteins", "Virion", "Virus", "cell growth regulation", "cell transformation", "combat", "crosslink", "design", "differential expression", "expectation", "gammaherpesvirus", "gene function", "insight", "leukemia/lymphoma", "mRNA Export", "messenger ribonucleoprotein", "mutant", "novel", "sarcoma", "transcriptome", "transforming virus", "triple helix", "viral DNA", "viral rescue" ], "approved": true } }, { "type": "Grant", "id": "10983", "attributes": { "award_id": "5R21AI158019-02", "title": "Viral Vectored COVID-19 Vaccines in a Guinea Pig Perinatal Infection Model", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 26420, "first_name": "MARY KATHERINE", "last_name": "Bradford", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-11-01", "end_date": "2023-10-31", "award_amount": 232500, "principal_investigator": { "id": 7397, "first_name": "YUYING", "last_name": "LIANG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 764, "ror": "https://ror.org/017zqws13", "name": "University of Minnesota", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 7398, "first_name": "Mark R.", "last_name": "Schleiss", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 764, "ror": "https://ror.org/017zqws13", "name": "University of Minnesota", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic has had a profound, global impact on public health. Of the 120,000,000 cases documented world-wide, over 30 million cases have occurred in the Unites States, with >530,000 COVID deaths to date. Considerable progress in control of the pandemic has been realized in the USA by licensure of three effective vaccines, and many additional immunization strategies are now in preclinical study and clinical trials. An emerging consensus is that an effective vaccine will require responses to the viral-encoded spike (S) protein, in particular, its receptor-binding domain (RBD). However, uncertainties remain about the optimal expression platform(s), as well as concerns for untoward effects conferred by vaccination, including the concern of potential antibody-dependent enhancement of infection. Another major issue is the need for vaccine-mediated protection of the pregnant patient and the fetus/neonate. Although congenital and perinatal transmission of SARS-CoV-2 infection has been documented, and serious COVID-19 disease in children is increasingly described, no strategy for immunization during pregnancy has been forthcoming. To help inform and direct future vaccine strategies for COVID-19 disease, we will address these areas of knowledge deficiency using a guinea pig model of SARS-CoV-2 vaccination. Our plan is to test hypotheses about optimized COVID-19 vaccine strategies using a Pichinde virus (PICV) vector. PICV is an enveloped RNA virus within the Arenavirus family and is not known to cause disease in humans or most animals. We have developed a PICV-based viral vector rP18tri and demonstrated it as a safe, effective, and versatile vaccine vector that elicits a balanced antibody and T cell response. We have preliminary data showing that a novel rP18tri-based SARS-CoV-2 S RBD domain vaccine can induce specific antibodies, including neutralizing antibodies, in mice. In Aim 1, we will test the hypothesis that this PICV-vectored vaccine (and other vaccines with improved antigen design) will demonstrate immunogenicity in guinea pigs, with enhanced immune responses compared to an MPL-adjuvanted RBD protein vaccine. We will compare mucosal, subcutaneous and intramuscular routes of immunization, comparing ELISA and neutralization titers. We will also include mucosal read-outs, including IgA responses, and will test the hypothesis that the PICV vector is associated with enhanced IFN-γ ELISPOT responses (compared to adjuvanted RBD vaccine). In Aim 2, we will examine vaccine safety and transplacental antibody transfer in neonatal guinea pigs following immunization in early pregnancy, comparing PICV vectored and subunit RBD vaccines in a dam-to-newborn antibody transfer model. We will examine serum from newborn pups to test the hypothesis that virus-neutralizing antibodies cross the placenta. These experiments have high relevance to human health, and will lay the groundwork for future SARS-CoV-2 challenge studies in the guinea pig pregnancy model that, in turn, can help clarify the optimal vaccine strategies to control congenital and perinatally-acquired COVID-19 disease in women and infants.", "keywords": [ "2019-nCoV", "Address", "Adjuvant", "Adult", "Animal Model", "Animals", "Antibodies", "Antibody-Dependent Enhancement", "Antigens", "Area", "Arenavirus", "Attention", "Award", "Biological Assay", "CD4 Positive T Lymphocytes", "CD8-Positive T-Lymphocytes", "COVID-19", "COVID-19 complications", "COVID-19 pandemic", "COVID-19 vaccination", "COVID-19 vaccine", "Cavia", "Cessation of life", "Child", "Clinical", "Clinical Trials", "Consensus", "Data", "Disease", "Enzyme-Linked Immunosorbent Assay", "Equilibrium", "Evaluation", "Family", "Fetus", "Future", "Generations", "Goals", "Health", "Histopathology", "Human", "Immune", "Immune response", "Immunity", "Immunization", "Immunoglobulin A", "Infant", "Infection", "Inflammatory", "Influenza", "Interferon Type II", "Intramuscular", "Knowledge", "Licensing", "Licensure", "Light", "Lymphocytic choriomeningitis virus", "Mediating", "Medical", "Methods", "Modeling", "Mucous Membrane", "Mus", "Neonatal", "Newborn Infant", "Patients", "Perinatal", "Perinatal Infection", "Perinatal transmission", "Pertussis", "Pichinde virus", "Placenta", "Pregnancy", "Pregnancy Complications", "Pregnancy Outcome", "Pregnant Women", "Protein Binding Domain", "Proteins", "Public Health", "RNA Viruses", "Reporting", "Reproductive Biology", "Reproductive Health", "Route", "SARS-CoV-2 infection", "SARS-CoV-2 spike protein", "SARS-CoV-2 transmission", "Safety", "Serum", "Syndrome", "System", "T cell response", "TNF gene", "Testing", "Uncertainty", "United States", "Vaccinated", "Vaccination", "Vaccines", "Variant", "Vasculitis", "Vertical Disease Transmission", "Viral", "Viral Vector", "Virus", "Woman", "Work", "Writing", "antibody transfer", "base", "clinical practice", "congenital infection", "coronavirus disease", "cytokine", "design", "disease transmission", "early pregnancy", "enzyme linked immunospot assay", "experimental study", "fetal", "guinea pig model", "immunogenicity", "improved", "maternal vaccination", "neonate", "neutralizing antibody", "novel", "pandemic response", "preclinical development", "preclinical study", "pregnant", "public health priorities", "public health relevance", "pup", "receptor binding", "response", "severe COVID-19", "subcutaneous", "success", "vaccination strategy", "vaccine candidate", "vaccine development", "vaccine safety", "vaccine strategy", "vaccine trial", "vaccine-induced antibodies", "vector", "vector vaccine" ], "approved": true } }, { "type": "Grant", "id": "5268", "attributes": { "award_id": "1R21AI158019-01A1", "title": "Viral Vectored COVID-19 Vaccines in a Guinea Pig Perinatal Infection Model", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 18568, "first_name": "JENNIFER L.", "last_name": "Gordon", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-11-01", "end_date": "2023-10-31", "award_amount": 193750, "principal_investigator": { "id": 18569, "first_name": "YUYING", "last_name": "LIANG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 18570, "first_name": "Mark R.", "last_name": "Schleiss", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 764, "ror": "https://ror.org/017zqws13", "name": "University of Minnesota", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic has had a profound, global impact on public health. Of the 120,000,000 cases documented world-wide, over 30 million cases have occurred in the Unites States, with >530,000 COVID deaths to date. Considerable progress in control of the pandemic has been realized in the USA by licensure of three effective vaccines, and many additional immunization strategies are now in preclinical study and clinical trials. An emerging consensus is that an effective vaccine will require responses to the viral-encoded spike (S) protein, in particular, its receptor-binding domain (RBD). However, uncertainties remain about the optimal expression platform(s), as well as concerns for untoward effects conferred by vaccination, including the concern of potential antibody-dependent enhancement of infection. Another major issue is the need for vaccine-mediated protection of the pregnant patient and the fetus/neonate. Although congenital and perinatal transmission of SARS-CoV-2 infection has been documented, and serious COVID-19 disease in children is increasingly described, no strategy for immunization during pregnancy has been forthcoming. To help inform and direct future vaccine strategies for COVID-19 disease, we will address these areas of knowledge deficiency using a guinea pig model of SARS-CoV-2 vaccination. Our plan is to test hypotheses about optimized COVID-19 vaccine strategies using a Pichinde virus (PICV) vector. PICV is an enveloped RNA virus within the Arenavirus family and is not known to cause disease in humans or most animals. We have developed a PICV-based viral vector rP18tri and demonstrated it as a safe, effective, and versatile vaccine vector that elicits a balanced antibody and T cell response. We have preliminary data showing that a novel rP18tri-based SARS-CoV-2 S RBD domain vaccine can induce specific antibodies, including neutralizing antibodies, in mice. In Aim 1, we will test the hypothesis that this PICV-vectored vaccine (and other vaccines with improved antigen design) will demonstrate immunogenicity in guinea pigs, with enhanced immune responses compared to an MPL-adjuvanted RBD protein vaccine. We will compare mucosal, subcutaneous and intramuscular routes of immunization, comparing ELISA and neutralization titers. We will also include mucosal read-outs, including IgA responses, and will test the hypothesis that the PICV vector is associated with enhanced IFN-γ ELISPOT responses (compared to adjuvanted RBD vaccine). In Aim 2, we will examine vaccine safety and transplacental antibody transfer in neonatal guinea pigs following immunization in early pregnancy, comparing PICV vectored and subunit RBD vaccines in a dam-to-newborn antibody transfer model. We will examine serum from newborn pups to test the hypothesis that virus-neutralizing antibodies cross the placenta. These experiments have high relevance to human health, and will lay the groundwork for future SARS-CoV-2 challenge studies in the guinea pig pregnancy model that, in turn, can help clarify the optimal vaccine strategies to control congenital and perinatally-acquired COVID-19 disease in women and infants.", "keywords": [ "2019-nCoV", "Address", "Adjuvant", "Adult", "Animal Model", "Animals", "Antibodies", "Antibody-Dependent Enhancement", "Antigens", "Area", "Arenavirus", "Attention", "Award", "Biological Assay", "CD4 Positive T Lymphocytes", "CD8-Positive T-Lymphocytes", "COVID-19", "COVID-19 complications", "COVID-19 pandemic", "COVID-19 vaccination", "COVID-19 vaccine", "Cavia", "Cessation of life", "Child", "Clinical", "Clinical Trials", "Consensus", "Data", "Disease", "Enzyme-Linked Immunosorbent Assay", "Evaluation", "Family", "Fetus", "Future", "Generations", "Goals", "Health", "Histopathology", "Human", "Immune", "Immune response", "Immunity", "Immunization", "Immunoglobulin A", "Infant", "Infection", "Inflammatory", "Influenza", "Interferon Type II", "Intramuscular", "Knowledge", "Licensure", "Light", "Lymphocytic choriomeningitis virus", "Mediating", "Medical", "Methods", "Modeling", "Mucous Membrane", "Mus", "Neonatal", "Newborn Infant", "Patients", "Perinatal", "Perinatal Infection", "Perinatal transmission", "Pertussis", "Pichinde virus", "Placenta", "Pregnancy", "Pregnancy Complications", "Pregnancy Outcome", "Pregnant Women", "Protein Binding Domain", "Proteins", "Public Health", "RNA Viruses", "Reporting", "Reproductive Biology", "Reproductive Health", "Route", "SARS-CoV-2 infection", "SARS-CoV-2 spike protein", "SARS-CoV-2 transmission", "Safety", "Serum", "Syndrome", "System", "T cell response", "TNF gene", "Testing", "Uncertainty", "United States", "Vaccinated", "Vaccination", "Vaccines", "Variant", "Vasculitis", "Viral", "Viral Vector", "Virus", "Woman", "Work", "Writing", "antibody transfer", "base", "clinical practice", "congenital infection", "coronavirus disease", "cytokine", "design", "disease transmission", "early pregnancy", "enzyme linked immunospot assay", "experimental study", "fetal", "immunogenicity", "improved", "maternal vaccination", "neonate", "neutralizing antibody", "novel", "pandemic disease", "porcine model", "preclinical development", "preclinical study", "pregnant", "public health priorities", "public health relevance", "pup", "receptor binding", "response", "severe COVID-19", "subcutaneous", "success", "vaccination strategy", "vaccine candidate", "vaccine development", "vaccine safety", "vaccine strategy", "vaccine trial", "vaccine-induced antibodies", "vector", "vector vaccine" ], "approved": true } }, { "type": "Grant", "id": "14622", "attributes": { "award_id": "1R01DK138055-01", "title": "Viral-immune interaction in glomerular kidney disease", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" ], "program_reference_codes": [], "program_officials": [ { "id": 22545, "first_name": "KEVIN E", "last_name": "Chan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-05-01", "end_date": "2029-02-28", "award_amount": 606134, "principal_investigator": { "id": 31304, "first_name": "David Changli", "last_name": "WEI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 851, "ror": "", "name": "UNIVERSITY OF TEXAS MED BR GALVESTON", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "Viral infection is a major contributor to the global burden of infectious diseases. Virus-related glomerular diseases are seen in increasing frequency in clinical practice but are still underrecognized, thus miss opportunities for timely treatment. Viral exposure can alter host immunity in subtle ways, leaving an indelible footprint on the immune system. While there have been many studies indicating the association of viral infection with glomerular disease, a direct involvement of virus in kidney barrier dysfunction is unknown in most cases. Among remarkable research obstacles, lacking of a convenient and relevant animal model can be the most alarming one. We have recently established a novel mouse model whereby viral proteins drive glomerular disease in concert with a unique immune molecule, soluble urokinase receptor (suPAR). Intranasal injection of SARS-Cov-2 spike S1 protein (2019-nCov) caused proteinuria and podocyte injury specifically in mice with high levels of suPAR. Treatment with anti-suPAR antibody in mice or anti- v 3 integrin antibody on human podocytes blocked proteinuria and protected the glomerular filtration apparatus respectively. Notably, we found this unique synergy between viral protein and host suPAR in causing glomerular disease applies to other integrin binding viruses as well, including HIV-1 and Epstein-Barr virus (EBV). Clinically, suPAR is associated with kidney function loss in patients with HIV-1 infection, and in those with moderate to severe Covid-19. Based on these intriguing new insights, we hypothesize that viral-host suPAR interplay induces glomerular integrin activation and plays an essential role in some virus-associated glomerular disease. We propose to test this hypothesis by comprehensively evaluating the implication of viral protein-suPAR-integrin triad in both mouse models (Aim 1) and virus-associated human glomerular diseases (Aim 2), utilizing state of the art tools, and unique combinations of top-down and bottom-up approaches. Additionally, we will test therapeutic modalities targeting the vicious viral protein-suPAR-integrin cycle with relevant small molecule inhibitors and antibodies (Aim 3).", "keywords": [ "2019-nCoV", "Affinity", "Animal Model", "Antibodies", "Binding", "COVID-19 pandemic", "COVID-19 patient", "Cell-Matrix Junction", "Cells", "Chronic Kidney Failure", "Clinical", "Communicable Diseases", "Coupled", "Data", "Devices", "Disease", "Epitopes", "Exposure to", "Fc Receptor", "Foot Process", "Frequencies", "Functional disorder", "Glomerular Filtration Rate", "HIV Envelope Protein gp120", "HIV-1", "Hantavirus Infections", "Hospitalization", "Human", "Human Herpesvirus 4", "Immune", "Immune system", "Immunity", "Impairment", "In Vitro", "Infection", "Influenza B Virus", "Injections", "Injury", "Integrin Binding", "Integrin Inhibition", "Integrins", "Interleukin-5", "Kidney", "Kidney Diseases", "Modality", "Modeling", "Molecular", "Monitor", "Mus", "Patients", "Photometry", "Play", "Proteins", "Proteinuria", "Publishing", "Renal function", "Renal glomerular disease", "Research", "Role", "SARS-CoV-2 infection", "SARS-CoV-2 spike protein", "Scanning", "Serology", "Signal Transduction", "Testing", "Therapeutic", "Therapeutic Intervention", "Ultrafiltration", "Urokinase Plasminogen Activator Receptor", "Viral", "Viral Proteins", "Virus", "Virus Diseases", "burden of illness", "clinical practice", "efficacy evaluation", "glomerular filtration", "in vivo", "innovation", "insight", "loss of function", "mouse model", "new therapeutic target", "next generation sequencing", "novel", "novel therapeutics", "overexpression", "podocyte", "renal damage", "severe COVID-19", "single-cell RNA sequencing", "small molecule inhibitor", "synergism", "therapeutic evaluation", "tool" ], "approved": true } }, { "type": "Grant", "id": "4872", "attributes": { "award_id": "1051655", "title": "Viroid models to study evolution of RNA trafficking motifs for host adaptation", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Biological Sciences (BIO)", "Symbiosis Infection & Immunity" ], "program_reference_codes": [], "program_officials": [ { "id": 16912, "first_name": "Michael", "last_name": "Mishkind", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2011-05-01", "end_date": "2014-04-30", "award_amount": 360000, "principal_investigator": { "id": 16913, "first_name": "Biao", "last_name": "Ding", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 308, "ror": "", "name": "Ohio State University", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 308, "ror": "", "name": "Ohio State University", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "Infectious RNAs including viroids and viruses must traffic between cells in order to establish systemic infection. This project addresses the role of noncoding RNA structural motifs for trafficking in host adaptation. It tests the hypothesis that (i) an infectious RNA can rapidly evolve new three-dimensional (3D) motifs for trafficking as a means of host adaptation, and (ii) different infectious RNAs can evolve distinct trafficking motifs for adaptation to the same host. This hypothesis was developed from the following observations. First, when a particular motif, called loop 19, of Potato spindle tuber viroid (PSTVd) was obliterated to abolish trafficking (but not replication) in the experimental host plant Nicotiana benthamiana, a new loop (loop 19*) evolved to restore trafficking. Second, some viroids, such as Hop stunt viroid (HSVd), differ significantly in sequences from PSTVd but also can infect N. benthamiana systemically. To test this hypothesis, the following experiments will be performed: 1) to elucidate the 3D structure of loop 19 and determine whether loop 19* is similarly structured, 2) to determine the cellular boundary at which loop 19 and loop 19* function, and 3) to perform a genome-wide mutational identification of HSVd trafficking motifs and compare them with the PSTVd motifs that have already been identified for similarities and differences.\n\nThis project will contribute new knowledge about the molecular mechanisms underlying the evolution of infectious RNAs and broadly the unifying and unique principles controlling the systemic trafficking of different RNAs. New research tools and experimental systems developed may also help transform research on the general principles of RNA structure-function relationships. This project will train undergraduate/graduate students in developing cutting-edge cross-disciplinary approaches to study fundamental biological problems, and help enhance science education for elementary/middle/high school students, including traditionally underrepresented groups.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "6623", "attributes": { "award_id": "1R43HD107718-01", "title": "Virtual Activities of Living for Occupational Rehabilitation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 22226, "first_name": "TOYIN DELE", "last_name": "Ajisafe", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-05-01", "end_date": "2023-04-30", "award_amount": 299790, "principal_investigator": { "id": 22227, "first_name": "Richard J.", "last_name": "Adams", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 1478, "ror": "", "name": "BARRON ASSOCIATES, INC.", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1478, "ror": "", "name": "BARRON ASSOCIATES, INC.", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true }, "abstract": "Introduction: The Virtual Activities of Living for Occupational Rehabilitation (VALOR) SBIR program will support telehealth delivery and remote monitoring of upper extremity (UE) stroke rehabilitation through the practice of virtual activities of daily living (ADLs) and instrumental ADLs (IADLs). The VALOR system marries ground- breaking untethered virtual reality (VR) headset technology and deep learning runtime 3D motion tracking with an existing suite of digital ADL/IADL content to enable functional, repetitive task practice at home with telehealth support. A key technological breakthrough is markerless tracking that employs cameras built into a low-cost VR headset, enabling patients to manually engage in virtual occupations using their affected UE. The VALOR Phase I program pursues two primary investigational objectives through a pilot study conducted by Duke University: (1) assess the usability and technology acceptance of immersive VR ADL/IADL practice for UE therapy by older adult stroke patients; and (2) establish the validity of immersive virtual ADL/IADL practice for tracking a patient's UE motor status to enable telehealth feedback and monitoring. Technical work in Phase I includes integration of a runtime neural network for real-time UE tracking with an existing suite of virtual ADLs/IADLs (originally developed for a non-immersive, PC-based system using the Kinect) to support immersive VR using a low cost standalone, untethered headset (no PC, no monitor, and no additional sensors required). Problem to be addressed: The COVID-19 pandemic exposed a critical lack of options for delivering an evidence-based UE intervention via telehealth. Innovative solutions are needed to enable patients to safely participate from home in a therapist-monitored therapy program. Approximately 50% of the >795,000 individuals hospitalized due to stroke each year in the U.S. suffer from chronic deficits in UE function [1], [2]. Existing clinical therapy systems for immersive VR are too expensive, complex, and/or bulky for use in patients' homes. Game consoles, exergames, or slipshod, non-evidence-based adaptations of VR technology do not address the integrated motor and cognitive skills required to achieve functional independence in daily living activities. Long-Term Goal: Improved outcomes and functional independence for patients with neurological injury. Phase I Summary: Phase I will produce a prototype VALOR system that consists of a mobile software application that runs on an Oculus Quest 2 untethered (i.e., wireless) VR headset. At least 3 immersive ADL/IADL activities will be fully integrated and tested, leveraging an existing library of virtual world assets from a non- immersive clinical VR system. A pilot study conducted by Duke University with stroke patients will demonstrate usability and technology acceptance, and investigate the hypothesis that metrics captured during immersive ADL/IADL practice will have high criterion validity with respect to gold standard measures of UE function. Commercial Opportunity: The VALOR product is poised to rapidly transition through well-established marketing and distribution channels to meet a critical need for evidence-based telehealth occupational therapy.", "keywords": [ "3-Dimensional", "Activities of Daily Living", "Address", "Adherence", "Adult", "Affect", "Articular Range of Motion", "Award", "Blinded", "COVID-19 pandemic", "Caring", "Cellular Phone", "Chronic", "Clinical", "Cognitive", "Complex", "Computer Vision Systems", "Computer software", "Data", "Elderly", "Environment", "Exercise", "Facebook", "Feedback", "Frequencies", "Goals", "Gold", "Hand", "Hand functions", "Healthcare", "Home", "Home environment", "Immersion", "Impairment", "Incidence", "Individual", "Intervention", "Interview", "Investigation", "Manuals", "Marketing", "Measures", "Methods", "Modeling", "Monitor", "Motion", "Motor", "Motor Skills", "Movement", "Nervous System Trauma", "Occupational", "Occupational Therapist", "Occupational Therapy", "Occupations", "Participant", "Patients", "Performance", "Phase", "Physicians", "Pilot Projects", "Process", "Provider", "Public Health", "Questionnaires", "Randomized Controlled Trials", "Recovery of Function", "Rehabilitation therapy", "Research", "Running", "Safety", "Small Business Innovation Research Grant", "Software Engineering", "Stroke", "System", "Technology", "Testing", "Time", "Universities", "Upper Extremity", "User-Computer Interface", "Video Games", "Wolves", "Work", "base", "cognitive function", "cognitive skill", "cost", "deep learning", "design", "digital", "dosage", "evidence base", "exercise program", "exergame", "experience", "functional independence", "functional status", "improved", "improved outcome", "individual patient", "innovation", "instrument", "instrumental activity of daily living", "mental imagery", "motor recovery", "neural network", "patient safety", "programs", "prototype", "psychologic", "remote monitoring", "repetitive task practice", "satisfaction", "sensor", "standard measure", "stroke outcome", "stroke patient", "stroke rehabilitation", "stroke therapy", "telehealth", "underserved area", "usability", "virtual", "virtual library", "virtual reality", "virtual reality environment", "virtual reality headset", "virtual reality sickness", "virtual reality system", "virtual world", "web app", "wireless" ], "approved": true } }, { "type": "Grant", "id": "12163", "attributes": { "award_id": "1I21HX003593-01A1", "title": "Virtual Care Coordination in VA Primary Care-Mental Health Integration", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2023-08-01", "end_date": "2025-01-31", "award_amount": null, "principal_investigator": { "id": 28029, "first_name": "Taona", "last_name": "Haderlein", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1708, "ror": "https://ror.org/05xcarb80", "name": "VA Greater Los Angeles Healthcare System", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Background: Among newly initiated Primary Care-Mental Health Integration (PC-MHI) patients, same day access to PC-MHI from primary care or other select medical clinics (e.g., emergency department/urgent care) is a Veterans Health Administration (VA) Strategic Analytics for Improvement and Learning (SAIL) performance measure (mnemonic: pcmhi7). Prompt initiation of mental health care after a medical visit increases the likelihood of subsequent mental health follow-up visits, enhancing quality of care. Yet, despite the rapid VA virtual care expansion during COVID-19, factors that influence virtual same day access to PC-MHI are unknown. Significance: Preliminary studies from this research group found that in a large VA medical center, PC-MHI same day access rates were nearly twice as high for in-person visits compared to virtual visits. Accordingly, PC-MHI patients who initiate care virtually may experience poorer medical and mental health outcomes from loss to follow-up. This finding reflects a knowledge gap that exists across disciplines in both VA and non-VA settings regarding effective strategies for virtual care coordination. The proposed study addresses multiple HSR&D Priority Areas: Access to Care, Mental Health, Primary Care Practice, Virtual Care/Telehealth. Innovation & Impact: The proposed research would be the first to characterize factors that influence same day access to PC-MHI among patients who use virtual care to initiate mental health services, including mutable clinic characteristics that may be amenable to intervention. By identifying specific predictors of same day access to PC-MHI from primary care, the proposed study will advance understanding of factors that affect virtual same day access while also identifying specific targets for future interventions, improving quality of care, and relatedly, medical and mental health outcomes, for Veterans who seek PC-MHI care virtually. Moreover, the study will advance scientific knowledge by providing data to inform strategies for effective interdisciplinary virtual care coordination. Specific Aims: 1) Identify multi-level characteristics associated with virtual and in-person PC-MHI same day access in a national VA sample. 2) Assess barriers, facilitators, and strategies for successful virtual care coordination in PC-MHI. Methodology: The study will use a mixed methods design. For Aim 1 (Quantitative), a national cohort of Veterans who initiated PC-MHI mental health services during FY2019 − FY2021 will be identified. PC-MHI same day access will be determined based on the presence or absence of a primary care or other select medical clinic visit on the same day as the initial PC-MHI appointment, per the Mental Health SAIL definition. A multi-level generalized linear model will be used to evaluate predictors of virtual and in-person same day access. For Aim 2 (Qualitative), semi-structured qualitative interviews with PC-MHI mental health providers and primary care providers from two VA healthcare systems (one urban, one rural) will be conducted to identify barriers, facilitators, and strategies for virtual care coordination in PC-MHI. Next Steps/Implementation: In partnership with the Office of Mental Health and Suicide Prevention, the Office of Connected Care, and the Office of Primary Care, the findings will be applied toward an HSR&D Merit Review Award grant proposal to develop an intervention to improve virtual care coordination in PC-MHI.", "keywords": [ "Accident and Emergency department", "Address", "Adoption", "Affect", "Ambulatory Care Facilities", "Applications Grants", "Appointment", "Area", "Award", "COVID-19", "COVID-19 pandemic", "Caring", "Characteristics", "Clinic", "Clinic Visits", "Clinical", "Communities", "Data", "Day Care", "Discipline", "Electronic Health Record", "Ethnic Origin", "Funding", "Future", "Goals", "Health Personnel", "Health Services Accessibility", "Healthcare Systems", "Intervention", "Interview", "Knowledge", "Learning", "Linear Models", "Measures", "Medical", "Medical Care Team", "Medical center", "Mental Health", "Mental Health Services", "Methodology", "Methods", "Modality", "Modeling", "Outcome", "Patient Care", "Patient-Focused Outcomes", "Patients", "Performance", "Persons", "Pilot Projects", "Primary Care", "Provider", "Quality of Care", "Race", "Reporting", "Research", "Risk", "Role", "Rural", "Sampling", "Scientific Advances and Accomplishments", "Services", "Specific qualifier value", "Structure", "Suicide prevention", "Telephone", "Time", "Urban Health", "Veterans", "Veterans Health Administration", "Visit", "care coordination", "cohort", "connected care", "design", "experience", "follow-up", "handbook", "health care settings", "improved", "innovation", "medical specialties", "primary care clinic", "primary care practice", "primary care provider", "primary care team", "research study", "rural healthcare", "telehealth", "therapy development", "urgent care", "video chat", "virtual", "virtual healthcare", "virtual patient", "virtual visit" ], "approved": true } } ], "meta": { "pagination": { "page": 1406, "pages": 1424, "count": 14236 } } }